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Enterohemorrhagic Escherichia coli, enteropathogenic E. coli, and Citrobacter rodentium are highly adapted
enteropathogens that successfully colonize their host’s gastrointestinal tract via the formation of attaching and
effacing (A/E) lesions. These pathogens utilize a type III secretion system (TTSS) apparatus, encoded by the
locus of enterocyte effacement, to translocate bacterial effector proteins into epithelial cells. Here, we report the
identification of EspJ (E. coli-secreted protein J), a translocated TTSS effector that is carried on the 5 end of
the cryptic prophage CP-933U. Infection of epithelial cells in culture revealed that EspJ is not required for A/E
lesion activity in vivo and ex vivo. However, in vivo studies performed with mice demonstrated that EspJ
possesses properties that influence the dynamics of clearance of the pathogen from the host’s intestinal tract,
suggesting a role in host survival and pathogen transmission.
Enterohemorrhagic Escherichia coli (EHEC), enteropatho-
genic E. coli (EPEC) (35), and Citrobacter rodentium (29) are
highly adapted enteropathogens that successfully colonize
their host’s gastrointestinal tract via the formation of attaching
and effacing (A/E) lesions (reviewed in references 13 and 28).
These lesions are characterized by the localized destruction
(effacement) of intestinal epithelial microvilli, an intimate at-
tachment between the bacterium and the host cell apical mem-
brane, and the formation of pedestal-like structures containing
high concentrations of actin (26) and intermediate filaments
(2) directly beneath sites of bacterial attachment. Formation of
A/E lesions is mediated by a filamentous type III secretion
system (FTTSS) apparatus (20, 42) responsible for the trans-
location of bacterial effectors into eukaryotic cells, where they
subvert host cell signaling (13). The TTSS apparatus is en-
coded on a pathogenicity island called the locus of enterocyte
effacement (LEE). The LEE was first described in EPEC
O127:H6 strain E2348/69 by McDaniel et al. (31) but is also
present in EHEC (36), rabbit-specific EPEC (44), and C. ro-
dentium (10).
The LEE also encodes six effector proteins, Tir, Map, EspF,
EspG, EspH, and SepZ, which are all translocated into the
host cell via the LEE-encoded FTTSS (11, 22, 24, 32, 45; James
Kaper, personal communication). Tir is inserted into the host
cell plasma membrane (22), where it functions as a bacterial
receptor for intimin (21), an outer-membrane bacterial adhe-
sion molecule (reviewed in reference 13). In the plasma mem-
brane, Tir adopts a hairpin-loop topology featuring a central
extracellular domain that binds intimin (17). The amino- and
carboxy-terminal domains of Tir are oriented in the host cell
cytoplasm, where they interact with host cytoskeletal and sig-
naling components (reviewed in reference 4). Map targets mi-
tochondria and has been suggested to disrupt their normal
function (24), and it also initiates filopodium formation imme-
diately upon interaction with the host cell via the GTPase
Cdc42 (23). In contrast, EspH represses filopodium formation
and enhances the formation of actin-rich pedestals (45). EspG
is a 44-kDa protein homologous to VirA, a translocated pro-
tein of Shigella flexneri that triggers host microtubule destabi-
lization but has an unknown role in virulence (11). EspF dis-
rupts intestinal barrier function (32) and therefore potentially
contributes to EPEC diarrhea. EspF also plays a role in epi-
thelial cell apoptosis (7). Importantly, all the LEE-encoded
effectors except Tir are dispensable for A/E lesion formation.
In addition, three non-LEE-encoded proteins named Cif
(cycle-inhibiting factor) (30), EspI/NleA (16, 34), and TccP
(Tir cytoskeleton coupling protein)/EspFu (5, 15) are translo-
cated via the LEE-encoded FTTSS. Cif is carried on a lamb-
doid phage and triggers an irreversible cytopathic effect in
HeLa cells, which is characterized by the progressive recruit-
ment of focal adhesions, assembly of stress fibers, and arrest of
the cell cycle (30). EspI/NleA is carried within prophage CP-
933P, localizes to the Golgi (16), and is required for full viru-
lence in the C. rodentium model (16, 34). TccP/EspFU is an
EHEC O157 effector that is carried on prophage CP-933U and
translocated into host cells, where it displays an Nck-like ac-
tivity (5, 15).
EHEC infection is associated with a range of symptoms from
nonbloody diarrhea, fever, and vomiting to bloody diarrhea
(hemorrhagic colitis) and hemolytic-uremic syndrome, a life-
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threatening condition. EPEC causes infantile nonbloody diar-
rhea in developing countries, and although EPEC and EHEC
share many genes implicated in virulence, EHEC, but not
EPEC, produces a potent cytotoxin, Shiga toxin (Stx), which is
responsible for the severe complications that characterize its
infection (reviewed in reference 35). EHEC and EPEC are
human pathogens, and as such, they are poorly pathogenic in
other animal species. At present, there is no natural small-
animal model that allows in vivo study of EHEC or EPEC.
However, C. rodentium, a mouse-specific pathogen that pos-
sesses the LEE pathogenicity island, causes transmissible co-
lonic hyperplasia (1; reviewed in reference 28), and induces
colonic A/E lesions indistinguishable from those caused by
EHEC and EPEC (40, 41), provides an excellent small animal
model to simulate in vivo infection for those two pathogens
(16, 34). In addition, neonatal- and weaned-lamb infection
models have recently been reported (48). Animals experimen-
tally infected with EHEC O157:H7 exhibited cecal and rectal
colonization with A/E, although the infection was not associ-
ated with clinical disease. Intimin has been shown to be essen-
tial for persistence of EHEC in lambs (48).
Recently, we monitored the global transcription profile of
EHEC O157:H7 (Sakai strain) during attachment to eukary-
otic plasma membranes (8). This has shown that the majority
of the LEE-genes were down-regulated in attached bacteria. In
addition, decreased levels of two mRNAs of adjacent genes,
Z3071 (Ecs2714) and Z3072 (Ecs2715), carried within pro-
phage CP-933U, were also detected (8). Importantly, Z3072
(TccP/EspFU) is present in EHEC but not in EPEC or C.
rodentium (5, 15), while Z3071 is present in EHEC, EPEC, and
C. rodentium, and its product is homologous to the type III
effector HopF of Pseudomonas syringae (43). The aim of this
study was to define the role of Z3071 in the pathogenesis of
A/E pathogens in vitro, ex vivo, and in vivo.
MATERIALS AND METHODS
Bacterial strains, plasmids, and growth conditions. The bacterial strains and
plasmids used in this study are shown in Table 1. Bacteria were grown in
Luria-Bertani (LB) medium or in Dulbecco’s modified Eagle’s medium. When
appropriate, additional antibiotics were added at the following concentrations:
ampicillin, 100 g/ml; kanamycin, 50 g/ml; nalidixic acid, 50 g/ml; and tetra-
cycline, 12.5 g/ml. Minimal medium consisted of M9 salts supplemented with
1% glucose.
Translocation assay. Translocation assays were performed as described by
Charpentier and Oswald (6). Wild-type and escF EPEC E2348/69 strains car-
rying derivatives of the pCX340 plasmid, a cloning vector encoding the mature
form of TEM-1 -lactamase, were subcultured in LB medium supplemented with
tetracycline and incubated for 16 h at 37°C. The cultures were diluted 1/100 in
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf serum
and 2 mM glutamine at 37°C for 3.5 h (preactivation). HeLa cells grown on glass
coverslips were infected with 1 ml of preactivated bacterial culture and incubated
at 37°C in 5% CO2. After 30 min of infection, IPTG (isopropyl--D-thiogalac-
topyranoside) was added at a final concentration of 1 mM, and the coverslips
were incubated for an additional hour. The cell monolayers were washed three
times with phosphate-buffered saline (PBS) and covered with 100 l of PBS plus
25 l of 6 CCF2/AM solution freshly prepared from the CCF2/AM Loading kit
(Invitrogen) (final concentration of CCF2/AM, 1 M). The cells were incubated
in darkness at room temperature for 2 h and then washed three times with PBS
and observed under a Nikon Eclipse E600 fluorescence microscope using a
UV-2A filter set (330- to 380-nm excitation). Pictures were taken using a Nikon
DXM1200 digital camera.
Construction of nonpolar espJ mutations. The EHEC 85–170 and C. roden-
tium espJ mutants were constructed by using a modification of the one-step
method (9). In each case, a part of the gene and the flanking regions from both
sides were amplified from the wild-type genomic DNA by PCR using the fol-
lowing pairs of primers (Table 2): for the EHEC mutant, EHEC-espJ-flank-f1
plus EHEC-espJ-flank-r1 (fragment 1) and EHEC-espJ-flank-f2 plus EHEC-espJ-
flank-r2 (fragment 2); for the C. rodentium mutant, Citro-espJ-flank-f1 plus
Citro-espJ-flank-r1 (fragment 1) and Citro-espJ-flank-f2 plus Citro-espJ-flank-r2
(fragment 2). For each mutant, the two PCR fragments (fragment 1 and frag-
ment 2) were digested with BamHI, ligated to each other, amplified, and cloned
into the cloning vector pGEMT. Then, in order to inactivate the gene and
facilitate mutant strain identification, the nonpolar aphT cassette (14) conferring
kanamycin resistance was inserted between the fused fragments (1 and 2) con-
tained in pGEMT, at the BamHI site. The inserts containing the aphT cassette
in the correct orientation were then amplified by PCR with primers EHEC-espJ-
flank-f1 and EHEC-espJ-flank-r2 for the EHEC mutant and Citro-espJ-flank-f1
and Citro-espJ-flank-r2 for the C. rodentium mutant. In order to enhance allelic
exchange, plasmid pKD46 was transformed into wild-type EHEC O157:H7 strain
85-170 and into wild-type C. rodentium strain ICC169 by electroporation, gen-
erating strains 85-170(pKD46) and ICC169(pKD46). The PCR product contain-
ing the flanking regions and the kanamycin resistance cassette was transformed
by electroporation into each wild-type strain containing the pKD46 plasmid.
Clones were grown on LB medium containing kanamycin to select for kanamycin
resistance. pKD46 was cured by growth at 42°C. Mutations were verified by PCR.
The EPEC E2346/69 espJ mutant was constructed by using the one-step
method (9). Briefly, a PCR product was generated by amplifying pKD4 template
plasmid using long primers (EPEC-espJ-pKD4-f and EPEC-espJ-pKD4-r) that
TABLE 1. Strains and plasmids used in this study
Name Description Reference or source
Strains
E2348/69 Wild-type EPEC O127:H6 27
ICC171 escF::Kan in E2348/69 47
85–170 EHEC O157:H7 stx 38
ICC169 Spontaneous naladixic acid-resistant derivative of wild-type C. rodentium 46
ICC188 espJ::Kan in 85–170 This study
ICC189 espJ::Kan in ICC169 This study
ICC190 espJ::Kan in E2348/69 This study
Plasmids
pCX340 pBR322 derivative; cloning vector used to fuse genes to blaM, which
encodes the mature form of TEM-1 -lactamase
6
pCX327 Derivative of pCX340 encoding a fusion of residues 1 to 16 of Cif to TEM-1 6
pICC283 Derivative of pCX340 encoding a fusion of EspJ to TEM-1 This study
pGEMT Cloning vector Promega
pSB315 Source of aphT cassette 14
pKD46 oriR101 repA101(Ts) blaM araBp-gam-bet-exo 9
pKD4 Template plasmid conferring kanamycin resistance 9
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corresponded to 20 nucleotides of pKD4 and 50 nucleotides of flanking DNA
regions homologous to the 5 and 3 ends of the espJ gene. The PCR product
contains a kanamycin resistance gene (derived from pKD4) flanked by 50-bp
sequences located upstream and downstream of the espJ gene. The PCR product
was then transformed by electroporation into EPEC E2348/69 containing the
pKD46 plasmid. Clones were grown on LB medium containing kanamycin to
select for kanamycin resistance. pKD46 was cured by growth at 42°C. Mutation
was verified by PCR.
FAS test and IVOC assay. Fluorescent actin staining (FAS) testing was per-
formed on infected HEp-2 cells as described by Knutton et al. (25). For the
human intestinal in vitro organ culture (IVOC) assay, tissue was obtained with
fully informed parental consent and local ethical committee approval using grasp
forceps during routine endoscopic (Fujinon EG/EC-41 pediatric endoscope)
investigation of intestinal disorders. Terminal ileal mucosal biopsy specimens
from the Peyer’s patch region that appeared macroscopically normal were taken
for organ culture experiments. Light microscopy subsequently showed no histo-
logical abnormality. IVOC infections were performed as described previously
(19). 85–170 espJ (ICC188) was examined using tissue from three patients (aged
46, 110, and 141 months). In each experiment, an uninoculated sample (to
exclude endogenous bacterial adhesion) and a positive control (IVOC with the
parental strain 85–170 to exclude host factors) were included. Samples were fixed
with 2.5% glutaraldehyde, postfixed in 1% aqueous osmium tetroxide, and pro-
cessed for viewing by a JEOL JSM 5300 scanning electron microscope.
Mice. Two murine models that differ in their susceptibility to C. rodentium
were used in this study. Female 6- to 8-week-old C57BL/6J mice and male 5- to
6-week-old C3H/HeJ mice were purchased from Harlan Olac (Bichester, United
Kingdom) and came from specific-pathogen-free stocks. During the course of
these studies, sentinel animals were screened for common murine pathogens
every 2 months. All animals were housed in individually HEPA-filtered cages
with sterile bedding and free access to sterilized food and water.
Oral infection of mice. Mice were orally inoculated using a gavage needle with
200 l of bacterial suspension (1010 CFU for C57BL/6J mice (46) and 2 
108 CFU for C3H/HeJ mice (34). The viable count of the inoculum was deter-
mined by retrospective plating on LB agar containing the appropriate antibiotic.
Independent experiments were performed at least twice using groups of at least
four mice per strain. Stool samples were recovered aseptically at various times
after inoculation, and the number of viable bacteria per gram of stool was
determined by plating the stool onto LB agar containing the appropriate anti-
biotics. At selected times postinfection, mice were killed by cervical dislocation.
The colon and cecum were aseptically removed and weighed after the removal of
fecal pellets and cecal contents. The organs were then homogenized mechani-
cally in 5 ml of sterile PBS using a Seward (London, United Kingdom) 80
stomacher, and the number of viable bacteria per gram of organ homogenate was
determined by plating the homogenate onto LB agar containing the appropriate
antibiotics.
Oral inoculation of sheep. Ten 6-week-old crossbred lambs were randomly
divided into two equal groups, supplied with food and water ad libitum, and
confirmed to be free of EHEC O157 by enrichment and O157 immunomagnetic
separation. All of the lambs were housed in biosecure containment level 2
accommodations. Each group was housed in a separate room with its own air
handling. The animals were visited only by experienced staff, who changed
clothing between groups. Five lambs were each dosed orally with either 109 CFU
of 85-170 Nalr or 85-170 espJ::Kanr resuspended in 10 ml of PBS (pH 7.4).
Approximately 24 h after the dosing, and as required thereafter for up to 27 days,
rectal fecal samples from each lamb were collected for direct plating onto
sorbitol-MacConkey (Oxoid) plates supplemented with either 15 g of nalidixic
acid/ml or 25 g of kanamycin/ml (Sigma). Samples that were negative on direct
plating were enriched in buffered peptone water for 6 h at 37°C and then plated
onto sorbitol-MacConkey plates supplemented with the appropriate antibiotic.
Representative colonies were confirmed to be E. coli O157 by latex agglutination
(Oxoid). All animal experiments were performed in accordance with the Animals
Scientific Procedures Act (1986) and were approved by the local ethical review
committee.
Statistics. The unpaired Student t test was used to compare normally distrib-
uted values from groups of animals. The nonparametric Mann-Whitney and
Kruskal-Wallis tests were used to compare nonnormally distributed values.
RESULTS
Z3071 is present in EHEC, EPEC, and C. rodentium, and its
product is similar to HopF, an effector protein of P. syringae.
Z3071 (Ecs2714) is located within the 5 end of the cryptic
prophage CP-933U in EDL933 (37) and RIMD 0509952 Sakai
(18), two clinical EHEC O157:H7 isolates that were recently
sequenced. Z3071 is also present in EPEC O127:H6 strain
E2348/69 (http://www.sanger.ac.uk/projects/Escherichia
_Shigella) and C. rodentium (http://www.sanger.ac.uk/Projects
/C_rodentium), but not in the E. coli K-12 genome (3), with
79.3 and 75.1% identity at the amino acid level, respectively.
Z3071 encodes a 217-amino-acid protein with unknown func-
tion and is located upstream of Z3072 (tccP/espFu), encoding
an EHEC type III effector protein that is required for EHEC-
induced actin polymerization (5, 15). Similar to tccP and most
of the LEE-located genes, Z3071 is also down-regulated in
bacteria closely attached to plasma membranes (8). Impor-
tantly, a search of the database revealed that Z3071 has 22%
identity with HopF, an effector protein of P. syringae (http://ca
.expasy.org; 43). The data suggested that Z3071 might be a
virulence factor of EHEC, EPEC, and C. rodentium, and it was
therefore chosen for further investigation.
Z3071 is translocated into epithelial cells. To determine
whether Z3071 is translocated into epithelial cells, the novel
TEM-1 translocation assay was applied (6). The system is
based on a translational fusion of effector proteins with a
mature TEM-1 -lactamase and the detection of TEM-1 ac-
tivity within eukaryotic cells by using the fluorescent -lacta-
mase substrate CCF2/AM. If translocation occurs, the transla-
tional fusion will be present in the eukaryotic cells, and the
cells will appear blue. If translocation does not occur, the cells
will appear green.
HeLa cell monolayers were infected with wild-type and
escF (ICC171) mutant (47) EPEC strains carrying the
pICC283 plasmid encoding the TEM-1 fusion with Z3071. In
addition, cells were infected with EPEC containing pCX340
(empty vector; negative control) or pCX327 (containing the
TABLE 2. Primers used in this study
Name Primer sequence (533)
EHEC-espJ-flank-f1 ........GAATTCAAGGTAGTAGTACTTATCTGC
EHEC-espJ-flank-r1 ........CGGGATCCCGATAATTGACATTATAAATGCCTT
EHEC-espJ-flank-f2 ........CGGGATCCCGGATACATCATGCTCTCTGAG
EHEC-espJ-flank-r2 ........CTGCAGTCATGCAGATTACCTTATAAG
Citro-espJ-flank-f1 ...........GAATTCTTCTAACACACCAGATCCTG
Citro-espJ-flank-r1 ...........CGGGATCCCGACAGTTTTCCTGTTTGTTCT
Citro-espJ-flank-f2 ...........CGGGATCCCGCATCATTACACTTCCAGAATC
Citro-espJ-flank-r2 ...........CTGCAGTTCACCAGGCATTGCGAAT
EPEC-espJ-pKD4-f.........CCAATCATAAAGAACTGCTTATCATCAATTAGTAACATATTACGCAACGAGTGTAGGCTGGAGCTGCTTC
EPEC-espJ-pKD4-r.........CATCCAGCCTGACTGTTTCTGGAAGTGTAATAATGAATGGTTCTCCCAGTCATATGAATATCCTCCTTAG
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first 16 residues of Cif; positive control) (6). Cells infected with
EPEC(pCX340) appeared green (data not shown), indicating a
lack of TEM-1 activity in these cells. Cells infected with
EPEC(pCX327) appeared blue (data not shown), indicating
that TEM-1 was translocated into the host cells. Cells infected
with EPEC carrying the translation fusion Z3071–TEM-1 also
appeared blue, indicating that Z3071 is a new translocated
effector (Fig. 1A). The translocation of Z3071 was dependent
on an active FTTSS, as a escF EPEC strain carrying the
EspJ–TEM-1 fusion appeared green, indicating that Z3071 is
translocated via the LEE-encoded FTTSS (Fig. 1B). In accor-
dance with the conventional nomenclature, we named Z3071
EspJ (for E. coli-secreted protein J).
EspJ is not required for the formation of A/E lesions in
vitro. In order to characterize the EspJ function, an espJ mu-
tant was generated in EHEC O157:H7 strain 85–170, EPEC
strain E2348/69, and C. rodentium ICC169 by deleting the open
reading frame. The resulting mutant strains were analyzed for
growth in vitro in both rich and minimal media and were found
to have growth rates identical to those of the parental strains,
as measured by optical density (data not shown).
An espJ mutant and the wild-type EHEC and EPEC strains
were assessed for A/E lesion formation in vitro. Infecting
HEp-2 cells with the mutant and the wild-type strains and
employing the FAS test (25) revealed actin-rich pedestals un-
der adherent EHEC espJ (strain ICC188) (Fig. 1C) and
EPEC espJ (strain ICC190) (data not shown) that were in-
distinguishable from those formed by the wild-type strains
(Fig. 1D), indicating that espJ is not required for this activity in
vitro.
EspJ is not required for the formation of A/E lesions ex vivo.
The IVOC adhesion assay is based on the infection of human
intestinal biopsy specimens with pathogens and offers a more
physiological model for EHEC-EPEC infection. Using this
model, Phillips et al. demonstrated that EHEC O157:H7 binds
to the follicle-associated epithelium of Peyer’s patches (39). In
order to assess the contribution of EspJ to the colonization of
human intestinal explants, espJ (ICC188) and 85–170 wild-
type strains were used to infect terminal ileal mucosal biopsy
specimens, which contained both villous and lymphoid follic-
ular areas. Bacterial adhesion was not seen on the uninocu-
lated negative control samples (Fig. 1E). The infection showed
that the espJ mutant attaches to and causes A/E lesions on
the follicle-associated epithelium of distal ileal samples (Fig.
1F), but not on ileal villous surfaces, a phenotype identical to
that of the parent strain, 85–170 (data not shown). Therefore,
EspJ is not required for A/E lesion activity ex vivo.
Contribution of EspJ to colonization of C3H/HeJ mice. In-
fection experiments were performed in the murine model to
determine the level of virulence of a C. rodentium espJ mu-
tant. The ability of the mutant strain to establish itself and
expand in mice was investigated by monitoring the viable
counts recovered from stools. In the sensitive C3H/HeJ mouse
strain, the espJ C. rodentium mutant (ICC189) produced the
classic growth curve previously reported for the wild-type
strain (1); however, the size of the challenging population
increased steadily to peak at ca. 109 to 1010 CFU g of stool1
at day 8, significantly higher than the levels for the wild-type
strain (P 	 0.019) (Fig. 2). Ten days postinfection, the mice
had become too ill for us to continue (as determined by weight
loss, piloerection, and lack of mobility), so the experiment was
terminated. The pathogen burdens of the organs of C3H/HeJ
mice (n 	 12) infected with the wild type and with ICC189
FIG. 1. In vitro analysis of EspJ. The translational fusion EspJ–
TEM-1 is translocated into HeLa cells infected with wild-type
EPEC(pICC283) (A) but not into HeLa cells infected with
ICC171(pICC283) (B). EspJ is not required for A/E lesion activity in
vitro, as indistinguishable actin-rich pedestals were observed under-
neath sites of bacterial adhesion in both the espJ mutant (C) and
EHEC 85–170 (D). EspJ is not required for A/E lesions activity ex
vivo. An uninfected follicle-associated epithelium devoid of bacteria is
shown in panel E, and ICC188-induced A/E lesions are shown in panel
F.
FIG. 2. Virulence of C. rodentium wild-type (ICC169) (solid sym-
bols) and espJ mutant (ICC189) (open symbols) strains in individual
sensitive C3H/HeJ mice as determined by viable counts in stools and
organ homogenates. *, significant differences were found in the viable
counts obtained from ICC169- and ICC189-infected mice recovered
from stools on day 8 postinfection and from the colons on day 10
postinfection.
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(espJ) were determined, as were the abilities of the strains to
cause hyperplasia. Mice infected with espJ had significantly
higher pathogen burdens in the colon than mice infected with
wild-type bacteria (6.86  109 
 1.96  109 compared to 4.32
 109 
 1.92 109 CFU g of organ homogenate1; P	 0.007)
but similar burdens within the cecum (2.70  109 
 1.67  109
compared to 2.01  109 
 1.13  109 CFU g of organ homog-
enate1; P	 0.273) (Fig. 2). However, there was no significant
difference between the induced levels of colonic hyperplasia, as
indicated by increased colon weight (data not shown).
Dynamics of clearance of C. rodentium espJ in C57BL/6J
mice. Since C3H/HeJ mice infected with espJ and wild-type
bacteria became too ill for us to follow the clearance of the
pathogens, the more resistant C57BL/6J strain was used to
follow the dynamics of colonization and clearance after infec-
tion (n 	 10). The ability of the espJ mutant strain (ICC189)
to establish itself and expand in mice was investigated by mon-
itoring the viable counts recovered from stools. For the first 10
days postinfection, the espJ mutant produced the classic
growth curve previously reported for the wild-type strain (46),
with the size of the challenging population increasing steadily
to peak at ca. 109 CFU g of stool1 on day 10 (Fig. 3A).
Fourteen days postinfection, the pathogen burdens of the or-
gans of infected mice were determined, as were the abilities of
the strains to cause hyperplasia. Mice infected with espJ bac-
teria had significantly higher pathogen burdens in the colon
than mice infected with wild-type bacteria (2.18  108 
 1.22
 108 compared to 4.80  107 
 5.73  107 CFU g of organ
homogenate1; P 	 0.05). Although the pathogen burdens
within the cecum were higher for mice infected with espJ
bacteria, this difference was not significant (9.73  107 
 1.13
 107 compared to 1.19  106 
 1.34  106 CFU g of organ
homogenate1; P 	 0.163) (Fig. 3B). Twenty days postinfec-
tion, mice infected with wild-type bacteria had completely
cleared infection in both the cecum and colon, as previously
described (46). In contrast, three out of five mice infected with
espJ bacteria still had bacteria present within the colonic
mucosa (ranging from 1.79 103 to 2.27 107 CFU g of organ
homogenate1). In addition, four out of five mice infected with
espJ still had bacteria present within the cecum (ranging from
1.41  103 to 1.42  107 CFU g of organ homogenate1) (Fig.
3B). However, there was no significant difference between the
induced levels of colonic hyperplasia, as indicated by increased
colon weight (data not shown), on either day 14 or day 20
postinfection.
The contribution of EspJ to the colonization of conventional
6-week-old lambs. Infection experiments were performed in
the conventional 6-week-old lamb model to determine the
persistence of E. coli O157:H7 strain 85–170 and an espJ mu-
tant. The abilities of the isolates to establish themselves and
persist in lambs were investigated by monitoring the viable
counts recovered in stools collected per rectum. Typically,
wild-type EHEC produced the classic shedding pattern (48),
persisting in relatively high numbers in the early stages of
infection and then declining until it became detectable in only
one lamb by day 9 postinfection (Fig. 4). EHEC was then
undetectable by direct plating or enrichment for the duration
of the study (27 days). In contrast, while EHEC espJ behaved
like the wild type in the early stages of infection, three lambs
still had detectable EHEC espJ on day 9 postinfection (Fig. 4)
and one lamb continued to shed bacteria (as detected by en-
richment) until the end of the study 27 days postinfection (data
not shown). However, these differences were not statistically
significant at any of the time points.
DISCUSSION
Using a DNA microarray specifically designed for E. coli
O157:H7, we have recently identified two novel genes (Z3071
and Z3072) implicated in virulence that are located adjacent to
each other within prophage CP-933U and are absent from the
E. coli K-12 genome (8). Further studies demonstrated that
Z3072 (TccP/EspFU) is a type III effector protein that has an
Nck-like activity following translocation, recruiting N-WASP,
FIG. 3. Virulence of C. rodentium wild-type (ICC169) (solid symbols) and espJ mutant (ICC189) (open symbols) strains in individual
C57BL/6J mice as determined by viable counts in stools (A) and organ homogenates (B). *, significant differences were found in the viable counts
obtained from ICC169- and ICC189-infected mice recovered from colons on day 14 postinfection. Twenty days postinfection, mice infected with
wild-type C. rodentium had completely cleared infection in both the cecum and colon, while three of five and four of five mice infected with ICC189
still had bacteria present within the colonic mucosa and cecum, respectively.
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Arp2/3 complex, and actin to the site of bacterial adhesion (5,
15). The purpose of this study was the characterization of the
role of Z3071 (EspJ) in virulence.
Of particular interest is the fact that, while espJ is found in
the genomes of EHEC O157:H7, EPEC, and C. rodentium, the
gene downstream, tccP/espFu, is found only in EHEC O157:
H7. Selective evolutionary pressures must have operated on
espJ and tccP/espFu in the genetic backgrounds of EPEC and
EHEC once prophage CP-933U was introduced which main-
tained espJ in EHEC O157:H7, EPEC, and C. rodentium and
espFU/tccP in EHEC O157:H7 only.
In this study, we have demonstrated, by employing the
TEM-1 reporter system, that EspJ is translocated into HeLa
cells (6). Therefore, espJ encodes the fourth identified TTSS
effector protein outside the LEE, after Cif (30), NleA/EspI
(16, 34), and TccP/EspFU (5, 15). In addition, by carrying out
in vitro and ex vivo adhesion assays, we have shown that EspJ
does not affect the A/E lesion phenotype, as indistinguishable
lesions were observed in both the espJ mutant and the wild-
type strain.
An unexpected effect of EspJ on virulence was revealed in
vivo. In the murine model of infection, higher levels of colo-
nization by the espJ mutant (ICC189) were found in the
gastrointestinal tract sites than for the wild-type strain in both
susceptible and more resistant mouse strains. As infection of
C3H/HeJ mice rendered the animals too ill to be followed for
extended periods, the dynamics of colonization by and clear-
ance of espJ were studied in the more resistant C57BL/6J
mice. This model indicates that the dynamics of clearance of
the espJ mutant and the wild type are very different. While
mice infected with wild-type bacteria had completely cleared
infection at 20 days postinfection, C. rodentium was still recov-
ered from the colon and cecum of mice infected with the espJ
mutant at the same time. It therefore appears that the espJ
mutant exhibits a more persistent colonization phenotype than
the wild-type strain. It is worth noting that the wild-type and
mutant strains grew equally well on LB and M9 minimal me-
dia, indicating that the phenotype obtained is not caused by a
higher growth rate. In addition, for both the wild-type and
espJ mutant strains, the symptoms of disease, including levels
of colonic hyperplasia, were identical. This suggests that the
phenotype of the espJ mutant may be due to a difference in
the dynamics of clearance of the colonizing bacteria and not
the initial inoculum or rates of progression of infection. Re-
cently, the dynamics of colonization and the subsequent clear-
ance of C. rodentium from orally infected mice were followed
by using bioluminescence imaging. In this study, it was shown
that the cecal patch is the first site to be colonized and the first
to be cleared, followed by colonization and clearance of the
colon. It has been suggested that this organ acts as a reservoir,
shedding bacteria into the colon (46).
It is important to note that C. rodentium mutants with dif-
ferent colonization and clearance dynamics in the murine
model have been previously reported (34). C. rodentium strains
lacking the genes espI (strain ICC179) and map (strains P6C6
and P10H2) exhibited a different colonization phenotype in
mice than wild-type bacteria, with viable counts recovered
from the stools over an extended period. However, these
strains also differ in their initial colonization dynamics, with the
mutant strains being slower to become established and hence
reaching a peak several days behind that of the wild-type
strain. In contrast, the rates of progression of colonization of
mice were identical for espJ and wild-type bacteria. In addi-
tion, the mutant map and espI strains also produced lower
levels of hyperplasia, whereas the level observed with the espJ
mutant was indistinguishable from that of the wild type. This
strengthens the observation that the espJ mutant exhibits a
clearance defect phenotype unrelated to its in vivo growth rate.
Colonization of the cecum and the colon is also a charac-
teristic of the infection of neonatal and weaned lambs with
EHEC O157:H7. Although this infection is not associated with
clinical disease, A/E lesions were detected in the cecum and
rectum in 6-week-old lambs infected with EHEC O157:H7
(48). Previous studies of 6-week-old lambs have confirmed a
FIG. 4. Shedding of EHEC O157 85–170 wild type (solid symbols) and a espJ mutant (open symbols) from orally infected individual
conventional lambs. By 9 days postinfection, the wild type was present in one out of five lambs, whereas the espJ mutant was present in three out
of five lambs.
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role for intimin in the persistence of EHEC O157:H7 in the
ovine intestine (48). In order to confirm the findings observed
in the murine infection model, we also infected 6-week-old
conventional lambs with the wild-type or espJ mutant E. coli
O157:H7 strain 85–170. In this model, the espJ mutant was
found to behave like the wild type in the early stages of infec-
tion but was recoverable from three out of five lambs on day 9
postinfection and persisted for 27 days postinfection in one
lamb, whereas the wild type was found in only one out of five
lambs 9 days postinfection. These data strengthen the obser-
vation that the espJ mutant exhibits a clearance defect pheno-
type.
Here, we report a TTSS effector that possesses properties
that influence the dynamics of clearance of the pathogen from
the host’s intestinal tract in a novel manner. Our data indicate
that the espJ mutant persists longer in mammalian hosts;
hence, the espJ gene exhibits “antivirulence” properties. Anti-
virulence genes have been described in other pathogens, in-
cluding Salmonella enterica (33) and Streptococcus pyogenes
(12), and two main hypotheses have been put forward for their
existence: they may favor host survival and thereby aid patho-
gen transmission, or they may contribute to pathogen fitness in
nonhost environments. Indeed, the Salmonella antivirulence
gene pcgL was found to be required for survival in nutrient-
limited environments (33). However, we found no such re-
quirement for espJ for growth in nutrient-poor media, and the
presence of C. rodentium espJ in the organs of mice after the
wild-type strain had been cleared suggests that in the case of
espJ a role in host survival, and hence in aiding pathogen
transmission, may be more likely.
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